Providing maximal therapeutic efficacy without toxicity is a universal goal of rational drug
therapy. However, substantial between‐patient variability in drug response often impedes …

Introduction: Sickle cell disease (SCD) is caused by a mutation in the HBB gene which is key
for making a component of hemoglobin. The mutation leads to the formation of an abnormal …

We aimed to investigate the clinical and genetic predictors of painful vaso‐occlusive crises
(VOC) in sickle cell disease (SCD) in Cameroon. Socio‐demographics, clinical …

Background Nursing science is essential to advance population health through contributions
at all phases of scientific inquiry. Multiple scientific initiatives important to nursing science …

Background and aims Preeclampsia is associated with reduced nitric oxide (NO)
bioavailability. Arginase is related to NO synthesis, but relatively unexplored in …

Abstract β‐Thalassemia is a genetic disorder caused by defects in the β‐globin gene
resulting in the absence or reduced synthesis of adult hemoglobin (HbA). Hydroxyurea is an …

Precision medicine enables the customization of patient care driven by experimental data
and knowledge about an individual or a population. Though the data can include omics data …

Background: Patients with sickle cell disease (SCD) are exposed to numerous drugs over
their lifespan, and many of these drugs have Clinical Pharmacogenetics Implementation …

Thalidomide has been shown to reactivate fetal hemoglobin (HbF) production and reduce
the need for blood transfusions in β-thalassemia patients. However, some patients show a …

In this short review we have presented and discussed studies on pharmacogenomics (also
termed pharmacogenetics) of the drugs employed in the treatment of β-thalassemia or Sickle …